
BioSight
Clinical-stage biotech developing novel therapeutics for hematological malignancies and disorders.
About
BioSight is a private, clinical-stage biotechnology company focused on developing innovative therapeutics for hematological malignancies and disorders. Their lead product, BST-236 (aspacytarabine), is a proprietary anti-metabolite designed to address unmet medical needs by enabling high-dose chemotherapy.
Show 6 more similar companies
Similar companies
Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
Shares Life Sciences, Biotech
AI-powered patient-centric drug simulations to accelerate and de-risk drug development.
Shares Life Sciences, Clinical Trials
Omnix Medical is developing a novel platform for advanced wound care management.
Shares Life Sciences, HealthTech
Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.
Shares Life Sciences, Biotech
Biotechnology company developing potentially curative cell therapies for cancer patients.
Shares Life Sciences, Biotech
Biotech company developing next-generation immunotherapy agents to unlock the immune system.
Shares Life Sciences, Biotech
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to BioSight?
People comparing tools land here. Get listed beside these.
Copy BioSight's SEO strategy
How often they publish, which searches their posts chase and their newest posts. Then outrank them.
All funding rounds
Key facts
- Website
- biosight-pharma.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 1999
- Employees
- 3
- Total funding
- $1.5M
- Business model
- B2B
Funding rounds
- $1.5M30 Jul 2008
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 30 Jul 2008 | Undisclosed round | $1.5M |
Tech stack
Detected on biosight-pharma.com, last scanned 16 Nov 2026. Run your own scan
- CMS / Builders
- Wix
- Email provider
- Microsoft 365
Benchmarking
See how your site ranks against 16,849 startups
BioSight sits in the 18th percentile for Domain Rating. Check where yours lands, free.
BioSight has a Domain Rating of 11, the 18th percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Bottom 25%
Check yoursAgent Readiness
Above median
Scan yoursSite Speed
Top 25%
PageSpeedData Trust
Below median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
BioSight scores 46. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentGet notified when BioSight changes
Used BioSight? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Are there companies like BioSight?
Yes. We list 6 companies like BioSight, including Upstream Bio, QuantHealth and Omnix Medical.
Is BioSight trustworthy and reputable?
StartupHub's Data Trust & Reputation score for BioSight is 58 out of 100, a use-caution rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has BioSight raised?
BioSight has raised a total of $1.5M in funding.
How many employees does BioSight have?
BioSight has approximately 3 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for BioSight:
Company details: from public sources. Funding: 1 round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch BioSight and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini

